Piramal

Headquarters: Mumbai

Founded: 1984 Employees: 6,579

Key companies:
 Piramal Enterprises Ltd
 Piramal Glass
 Piramal Realty
 Piramal Foundation

Key Services: Pharmaceutical Healthcare, Life Sciences, Housing, Capital, Healthcare

Information Management

Offices in over 30 countries and global brand presence in more than 100 markets.

Over 10,000 employees from 21 diverse nationalities.

Key People: Ajay Piramal, Chairman | Swati Piramal, Vice Chairperson

Core Values:

1. Knowledge- strive for a deeper understanding of our domain and aspire to do things
creatively.
2. Action- empowered to act decisively and create value and be consistent in our
thought, speech and action.
3. Care- enhance the interests of our customers, community, employees, partners and
shareholders, and strive to be the best and be humble
4. Impact- Strive to achieve market leadership in scale and profitability, wherever we
compete and build lasting businesses.

Purpose:

‘Doing Well and Doing Good’

We believe that individual success and organisational growth cannot be mutually exclusive
from responsible and ethical business practices.

 Serving people
 Making a positive difference
 Living our values
 The Piramal brand is represented by the Gyan Mudra. It is an aesthetic
hand posture practiced in yoga, meditation and dance. Each finger
represents one of the five elements (Air, Water, Earth, Fire and Sky)

Together, they aspire to form a circle of perfection, peace and happiness,

In the logo, the Gyan Mudra represents our core values of Knowledge,
Action, Care & Impact.

Piramal Enterprises (PEL)

Piramal Enterprises Limited (PEL) has diversified business interests in Financial Services and
Pharmaceuticals. PEL’s consolidated revenues were US$1.7 billion in FY2020, with ~34% of
revenues generated from outside India. PEL offers a wide range of financial products and
solutions, with exposure across both wholesale and retail financing.
Piramal Pharma Limited (PPL), a subsidiary of PEL, operates across 14 global facilities and a
global distribution network in over 100 countries.
It includes Pharma Solutions, an integrated contract development and manufacturing
(CDMO) business and Critical Care, a complex hospital generics business
Competitors: GSK, Revital, Pfizer, Ciplamed, Zuventus HealthCare, Merck, BMS, Johnson &
Johnson, Novartis, Sun Pharma.
Piramal Glass
Piramal Glass is a manufacturer of glass packaging for the pharmaceuticals, foods &
beverages (F&B) and cosmetics & perfumery (C&P) industries, services. Piramal Glass has
manufacturing plants in USA, Sri Lanka and India and is the largest speciality glass player in
Asia. It pioneered digitalisation in manufacturing in India
Competitors: GlassPak, Daggett and California Glass Studio.
Piramal Realty
Piramal Realty is a fully owned real estate venture of Piramal Group and has over 15 Million
sq.ft. of land under development in both commercial and residential projects across prime
areas in Mumbai and Thane.
Competitors: D R Reality, United Realty And Construction, Afcons, Killebrew And Company
Realty, Covai Property Centre, L&T Hydrocarbon Engineering, BioMed Realty, L.P.
Piramal Foundation
The Piramal Foundation is a private philanthropic foundation established in 2006. It
collaborates with governments, corporates and philanthropists to address India’s prevalent
issues through innovative solutions.
Recent News:
Piramal Enterprises Q2 results: Profit rises 14% to Rs 628.31 crore
https://economictimes.indiatimes.com/markets/stocks/earnings/piramal-enterprises-q2-
results-profit-rises-14-to-rs-628-31-crore/articleshow/78911105.cms
PPL and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in
Convergence Chemicals
http://www.equitybulls.com/admin/news2006/news_det.asp?id=276340
Carlyle buys 20% stake in Piramal Pharma for ₹3,523 crore
https://www.livemint.com/companies/news/carlyle-buys-20-in-piramal-pharma-for-rs-3-
523-crore-11601991387574.html
Blackstone makes $ 800 mn play for Piramal Glass business
https://economictimes.indiatimes.com/news/company/corporate-trends/blackstone-
makes-800-million-play-for-piramal-glass-business/articleshow/78942695.cms
Piramal Housing Finance notifies CCI of proposed DHFL bid
https://economictimes.indiatimes.com/news/company/corporate-trends/piramal-housing-
finance-notifies-cci-of-proposed-combination-with-dhfl/articleshow/78917775.cms

CSR:

 Primary Healthcare & Nutrition – Piramal Swasthya

 Education Leadership and Women & Youth Empowerment – Piramal School of
Leadership
 Access to Safe Drinking Water – Piramal Sarvajal
https://www.piramal.com/foundation/

Competitions –
Pharma

 GSK
 Pfizer
 Cipla Med
 J&J
 Sun Pharma
 AstraZeneca
 Sanofi
Glass Manufacturing –

 Saverglass
 Anchor Glass Container
 Vetropack

Reality –

 AFCONS Infrastructure Limited

 Godrej Properties Limited
 Oberoi Realty Limited
 Brigade Enterprises Limited

SWOT Analysis of Piramal Group –

Strengths –

 Indian pharmaceutical and health care company with Piramal Enterprises is also one
of the largest custom manufacturing companies across the World
 High investment in R & D, Piramal Enterprises has a global R&D division in NY, a
facility in India, and a manufacturing plant in Bethlehem
 High Brand equity in healthcare industry
 Piramal Healthcare is one of the fastest growing players by sales domestic consumer
healthcare market, which deals with non-prescription products in the healthcare and
wellness segment.
 Good product portfolio and a strong workforce
Weakness –

 Weak global presence compared to global players

 Due to high competition brand has limited market share

Opportunity –

 Global presence by expansion

 Healthcare sector is booming industry, expanding in this sector is a viable option
 Acquisition of smaller players to enhance market share

Threat –

 Advanced Technologies constantly demanding product innovation

 Long pending approval time from the FDA and local government
STP –
Segmentation - Individuals and corporates seeking pharma products
Target Market - Middle class and upper-class individuals
Positioning – Quality and affordable pharmaceutical products

Financial Numbers –
Revenue: INR 13,068 Crores (59% from Financial Services & 41% from Pharma)
Total Assets – Rs. 74,909 Crore
Net Worth – Rs. 30, 572 Crore
Net Profit – Rs. 2,615 Crore
Revenue CAGR – 28%